Predictive Role of ERCC1 Expression in Head and Neck Squamous Cell Carcinoma Patients Treated with Surgery and Adjuvant Cisplatin-Based Chemoradiation
| Autor: | Patrizio Pasqualetti, Alfredo Fabiano, Luca Marmiroli, Diego Signorelli, Domenico Corsi, Radici M, Angelo Camaioni, Giorgio Mazzarella, Ilaria Simonelli, Marco Ciaparrone, Curzio Pianelli, Piera Catalano, A. Mecozzi, Giulio Bicciolo, Luca de Campora, Orietta Caspiani |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Oncology
Male Cancer Research medicine.medical_specialty medicine.medical_treatment Disease-Free Survival Predictive Value of Tests Internal medicine medicine Carcinoma Humans Genetic Predisposition to Disease Cisplatin business.industry Head and neck cancer General Medicine Chemoradiotherapy Adjuvant Middle Aged medicine.disease Endonucleases Prognosis Head and neck squamous-cell carcinoma Immunohistochemistry DNA-Binding Proteins Head and Neck Neoplasms Predictive value of tests Carcinoma Squamous Cell Female ERCC1 Neoplasm Recurrence Local business Adjuvant Chemoradiotherapy medicine.drug |
| Zdroj: | Oncology. 89(4) |
| ISSN: | 1423-0232 |
| Popis: | Objective: ERCC1 (excision repair cross-complementation group 1) expression predicts survival in patients with locally advanced head and neck squamous cell carcinoma (HNSCC) treated with chemoradiation. In order to evaluate the predictive role in the adjuvant setting, we investigated ERCC1 expression in radically resected HNSCC patients who underwent surgery and cisplatin chemoradiation. Methods: ERCC1 expression levels were determined by immunohistochemistry in primary tumor tissues from 48 patients with stage III-IV cancers. The median follow-up was 38.5 months (range: 5-121). Results: High ERCC1 expression was observed in 36 (75%) patients. Univariate analysis showed that patients with high levels of ERCC1 had significantly worse disease-free survival and overall survival (OS) than patients with low levels (HR = 7.15; 95% CI, 1.68-30.35; p = 0.008 and HR = 9.90; 95% CI, 1.33-73.96; p = 0.025, respectively). In the multivariate analysis, high ERCC1 expression (HR = 7.36; 95% CI, 1.72-31.4; p = 0.007) together with high-risk category (HR = 2.69; 95% CI, 1.01-7.18; p = 0.048) were the best predictors for relapse. High ERCC1 expression was the only unfavorable independent determinant for OS (HR = 9.53; 95% CI, 1.27-71.35; p = 0.028). Conclusions: This investigation suggests that ERCC1 expression might be useful to predict prognosis in radically resected HNSCC patients treated with surgery and chemoradiation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|